- Home
- MAS vs ILMN Comparison
MAS vs ILMN Comparison
Compare MAS & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAS
- ILMN
- Stock Information
- Founded
- MAS 1929
- ILMN 1998
- Country
- MAS United States
- ILMN United States
- Employees
- MAS N/A
- ILMN N/A
- Industry
- MAS Industrial Specialties
- ILMN Medical Specialities
- Sector
- MAS Industrials
- ILMN Health Care
- Exchange
- MAS Nasdaq
- ILMN Nasdaq
- Market Cap
- MAS 16.7B
- ILMN 15.9B
- IPO Year
- MAS N/A
- ILMN 2000
- Fundamental
- Price
- MAS $71.04
- ILMN $81.88
- Analyst Decision
- MAS Buy
- ILMN Buy
- Analyst Count
- MAS 13
- ILMN 18
- Target Price
- MAS $86.65
- ILMN $141.94
- AVG Volume (30 Days)
- MAS 2.2M
- ILMN 2.2M
- Earning Date
- MAS 04-23-2025
- ILMN 05-01-2025
- Dividend Yield
- MAS 1.75%
- ILMN N/A
- EPS Growth
- MAS N/A
- ILMN N/A
- EPS
- MAS 3.76
- ILMN N/A
- Revenue
- MAS $7,828,000,000.00
- ILMN $4,372,000,000.00
- Revenue This Year
- MAS N/A
- ILMN $0.69
- Revenue Next Year
- MAS $3.89
- ILMN $4.91
- P/E Ratio
- MAS $18.88
- ILMN N/A
- Revenue Growth
- MAS N/A
- ILMN N/A
- 52 Week Low
- MAS $63.81
- ILMN $77.54
- 52 Week High
- MAS $86.70
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- MAS 46.66
- ILMN 35.35
- Support Level
- MAS $67.84
- ILMN $77.54
- Resistance Level
- MAS $70.89
- ILMN $89.95
- Average True Range (ATR)
- MAS 1.43
- ILMN 2.91
- MACD
- MAS 0.17
- ILMN 0.63
- Stochastic Oscillator
- MAS 81.84
- ILMN 34.97
Stock Price Comparison Chart: MAS vs ILMN
About MAS Masco Corporation
Masco manufactures a variety of home improvement and building products. The company's $5-billion plumbing segment, led by the Delta and Hansgrohe brands, sells faucets, showerheads, and other related plumbing fixtures and components. The $3-billion decorative architectural segment primarily sells paints and other coatings under the Behr and Kilz brands, but it also sells builder hardware and lighting products.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.